Methotrexate Pharmacokinetics and Survival in Osteosarcoma

Pediatric Blood and Cancer

Volumn 42, Issue 1, 2004, Pages 52-58

  Aquerreta, Irene ^a   Aldaz, Azucena ^a   Giráldez, Joaquín ^a   Sierrasesúmaga, Luis ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

High dose methotrexate; Osteosarcoma; Pharmacokinetics; Tumor response

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIEMETIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; COTRIMOXAZOLE; DACTINOMYCIN; DIURETIC AGENT; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; VANCOMYCIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; OSTEOSARCOMA; OUTCOMES RESEARCH; PARAMETER; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SURVIVAL RATE; TUMOR NECROSIS;

EID: 0842283258     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.10443     Document Type: Article

References (34)

1. French Bone Tumor Study Group. Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combination and early prophylactic lung irradiation. Cancer 1998;61:1304-1311.
2. Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate. J Clin Oncol 1991;9:1766-1775.
3. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12(7):1443-1451.
4. Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996;78:2127-2135.
5. Kawai A, Sugihara S, Kunisada TM, et al. The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma. Arch Orthop Trauma Surg 1996;115(2):68-70.
6. Evans WE, Crom WR, Stewart CFP, et al. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia. Lancet 1984;1:359-362.
7. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl J Med 1986;314:471-477.
8. Borsi JD, Moe PJ. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 1987;60:3020-3024.
9. Borsi JD, Revesz T, Schuler D. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1987;19:261-264.
10. Evans WE, Rodman JH, Relling MV, et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991;28:15-21.
11. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
12. Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology: Problems and potential in antineoplasic therapy. Clin Pharmacokinet 1987;13:205-227.
13. Grem JL, King SA, Wittes RE, et al. The role of methotrexate in osteosarcoma. J Natl Cancer Inst 1988;80:626-655.
14. Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastasic osteosarcoma: A report from the Childrens Cancer Study Group. Med Pediatr Oncol 1987;15:69-77.
15. Winkler K, Beron G, Delling G. Neoadjuvant chemotherapy of sarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based in histological tumor response. J Clin Oncol 1988;6:329-337.
16. Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate: A Scandinavian Sarcoma Group Study. J Clin Oncol 1991;9:1766-1775.
17. Delepine N, Delepine G, Cornille H, et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995;15:489-494.
18. Delepine N, Delepine G, Jasmin C, et al. Importance of age and methotrexate dosage: Prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988;42:257-262.
19. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1988;16(2):658-663.
20. - lymphoblasts: Relationship of dose and duration of the exposure to tumor cell viability. Cancer Res 1982;42:1641-1645.
21. Schwartz GJ, Haycock GB, Edelman CM, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-263.
22. Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Spokane, WA: Principles of Therapeutic Drug Monitoring, Inc.; 1992. pp 29-1 to 29-42.
23. TDx™ Assays Manual. Abbott Park, IL: Abbott Laboratories; 1991.
24. Jelliffe RW, Schumitzky A, Van Guilder M. 1999. Making parametric population PK/PD models: The Iterative bayesian (IT2B) algorithm. Technical report. Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, CA.
25. Jelliffe RW, Schumitzky A, Van Guilder M. 1999. Making non-parametric population PK/PD models: The NPEM algorithm. Technical report. Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, CA.
26. Jelliffe RW, Tahani B. 1992. A library of serum drug assay error patterns, and some suggestions for improved modeling and simulation of pharmacokinetic behaviour. Technical report: 92-5. Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, CA.
27. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667-1672.
28. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustments. Methods in clinical trials. Stat Med 1997;16:2529-2542.
29. STATISTICA. Tulsa, OK: Stat Soft™, Inc.; 1994. Volumes I-IV.
30. Link MP, Eilberg F. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Lippincott-Raven, Inc.; 1997. pp 889-920.
31. Frei E III, Blum RH, Pitman SW, et al. High-dose methotrexate with leucovorin rescue: Rationale and spectrum of antitumor activity. Am J Med 1980;68(3):370-376.
32. Bacci G, Ferrari S, Longhi A, et al. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001;8(4):883-888.
33. Breithaupt H, Küenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 1982;66:1733-1741.
34. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastasic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.